Figure 7. Glutamine antagonism increases tumor antigen cross-presentation to T cells by macrophages.

(A) WT (3 × 10⁵) or Batf3-KO BMDMs (3 × 10⁵) and 5 × 10⁴ B16-OVA tumor cells were cocultured in the presence or absence of 1 μM DON. After 24 hours of incubation, supernatants were discarded and 3 × 10⁵ eFluor 450–labeled naive CD8⁺ T cells from OTI mice were added. Histogram of divided cells from CD8⁺ T cells analyzed by flow cytometry. (B and C) MC38 cells (5 × 10⁵) were implanted subcutaneously into the flank of WT C57BL/6J mice or Batf3-KO mice. MC38 tumor–bearing mice were treated with JHU083 (0.3 mg/kg) daily starting on day 14 after tumor inoculation. (B) On day 21, tumor weight was recorded (left), and percentage change in tumor volume was calculated (right). (C) On day 21, tumors were harvested and CD8⁺ T cells were analyzed by flow cytometry. Data are representative of 3 independent experiments and are presented as the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001 by 1-way ANOVA with Tukey’s multiple-comparisons post hoc test (B) or unpaired t test (C).